Authors

Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center

Latest:

Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancer

Alexander Drilon, MD presents data from the 2021 American Society of Clinical Oncology annual meeting from trials in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer treated with larotrectinib.

Alexander E. Drilon, MD

Latest:

Dr. Drilon on Activity of Larotrectinib in TRK Fusion-Positive NSCLC

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive non–small cell lung cancer.

Alexander E. Perl, MD

Latest:

Dr. Perl on CAR T Cells in Pediatric Leukemia

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, Perelman School of Medicine, discusses the promise of CAR T cells in the treatment of pediatric leukemia.

Alexander E. Perl, MD, MS

Latest:

Dr. Perl on Genetic Testing and Targeted Therapies in AML

Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.

Alexander E. Perl, MD, MS, Hospital of The University of Pennsylvania

Alexander E. Perl, MD, Perelman School of Medicine

Alexander Eggermont, MD, PhD, Institut Gustave Roussy

Alexander Guminski, MD, PhD

Latest:

Dr. Guminski on 16-Month Follow-Up With Cemiplimab in mCSCC

Alexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.

Alexander I. Sankin, MD

Latest:

Dr. Alexander I. Sankin on HHLA2 in Bladder Cancer

Alexander J. Stratigos, MD

Latest:

Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCC

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.

Alexander Kutikov, MD

Latest:

Fox Chase Investigates Screening Methods to Avoid Unnecessary Radical Cystectomy

Currently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.

Alexander Kutikov, MD, FACS

Latest:

Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy

Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.

Alexander Leandros Lazarides, MD

Latest:

Dr. Lazarides on Research Regarding Margin Assessment in Sarcoma

Alexander Leandros Lazarides, MD, discusses research regarding margin assessment in patients with sarcoma.

Alexander M. Lesokhin, MD

Latest:

Dr. Lesokhin on the Utility of Elranatamab in Relapsed/Refractory Multiple Myeloma

Alexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.

Alexander M. M. Eggermont, MD, PhD

Latest:

Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Alexander N. Shoushtari, MD

Latest:

Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma

Alexander N. Shoushtari, discusses the rationale for the phase 3 CheckMate-067 trial in advanced melanoma.

Alexander Perl, MD, Abramson Cancer Center, University of Pennsylvania

Alexander Perl, MD, Perelman School of Medicine, University of Pennsylvania

Alexander R. Menter, MD

Latest:

Dr. Menter on Neoadjuvant Immunotherapy in Early-Stage NSCLC

Alexander R. Menter, MD, oncologist, Kaiser Permanente, discusses the use of neoadjuvant immunotherapy in patients with early-stage non–small cell lung cancer (NSCLC).

Alexander Ring, MD

Latest:

Dr. Ring on Molecular Profiling of CTCs in Advanced Breast Cancer

Alexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.